This paper is in the following e-collection/theme issue:

Theme Issue: Novel Coronavirus (COVID-19) Outbreak Rapid Reports (1484) JMIR Theme Issue: COVID-19 Special Issue (2394)

Published on in Vol 6, No 3 (2020): Jul-Sep

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/19538, first published .
Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir

Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir

Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir

Authors of this article:

Guosheng Yin1 Author Orcid Image ;   Chenyang Zhang1 Author Orcid Image ;   Huaqing Jin1 Author Orcid Image
Article Authors Cited by (3) Tweetations (1) Metrics

Guosheng Yin   1 , PhD ;   Chenyang Zhang   1 , MSc ;   Huaqing Jin   1 , BSc

1 Department of Statistics and Actuarial Science, The University of Hong Kong, Hong Kong, China (Hong Kong)

Corresponding Author:

  • Guosheng Yin, PhD
  • Department of Statistics and Actuarial Science
  • The University of Hong Kong
  • Run Run Shaw Building
  • Pokfulam Road
  • Hong Kong, 000000
  • China (Hong Kong)
  • Phone: 852 39178313
  • Fax: 852 28589041
  • Email: gyin@hku.hk